Tracking the insidious course of Alzheimer's disease

Nature Medicine

Volumn 18, Issue 9, 2012, Pages 1342-1343

  Kosik, Kenneth S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HUMAN; NOTE; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ARTICLE; BRAIN; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN; DISEASE PROGRESSION; HUMANS; RESEARCH DESIGN; TAU PROTEINS;

EID: 84868642306     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2922     Document Type: Note

References (7)

1. Bateman, R.J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. doi:10.1056/NEJMoa1202753 (11 July 2012).
2. Jack, C.R. Jr. et al. Hypothetical model of dynamic biomarkers of Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128 (2010).
3. Golde, T.E. et al. Anti-Atherapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron 69, 203-213 (2011).
4. Lopera, F. et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. J. Am. Med. Assoc. 277, 793-799 (1997).
5. Acosta-Baena, N. et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol. 10, 213-220 (2011).
6. Cramer, P.E. et al. ApoE-directed therapeutics rapidly clear ?-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506 (2012).
7. US Food and Drug Administration. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm071590.pdf (2007).